**Core Concept**
The efficacy of a new drug is confirmed through a rigorous testing process involving multiple phases of clinical trials, which assess its safety and effectiveness in humans. Phase I through III trials evaluate various aspects of the drug's performance, but the primary goal of Phase III is to confirm its efficacy in a large, diverse population.

**Why the Correct Answer is Right**
Phase III clinical trials are the final stage before a new drug is submitted for regulatory approval. These trials involve a large number of participants (typically several hundred to several thousand) and are designed to confirm the efficacy of the drug in a diverse population. The primary outcome measures in Phase III trials are typically compared to a placebo or an active control, and the results are used to support the drug's safety and efficacy claims.

**Why Each Wrong Option is Incorrect**
**Option A:** Phase I trials primarily focus on assessing the safety and tolerability of a new drug in a small group of healthy volunteers or patients, and are not designed to evaluate its efficacy.
**Option B:** Phase II trials are used to evaluate the efficacy and safety of a new drug in a larger group of patients, but are not as comprehensive as Phase III trials.
**Option C:** Phase IV trials are conducted after a drug has been approved and marketed, and are designed to monitor its long-term safety and efficacy in a real-world setting.

**Clinical Pearl / High-Yield Fact**
When evaluating the efficacy of a new drug, it's essential to understand the differences between Phase II and Phase III trials. Phase II trials are often used to evaluate the efficacy of a drug in a specific patient population, while Phase III trials provide more generalizable evidence of its efficacy in a larger, more diverse group of patients.

**Correct Answer: C. Phase III trials confirm the efficacy of a new drug in a large, diverse population.**